Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 16;109(9):857-863.
doi: 10.1093/bjs/znac217.

Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey

Maria Luisa Gasparri  1   2 , Jana de Boniface  3   4 , Philip Poortmans  5   6 , Oreste D Gentilini  7 , Orit Kaidar-Person  8   9   10 , Maggie Banys-Paluchowski  11   12 , Rosa Di Micco  7 , Laura Niinikoski  13 , David Murawa  14 , Eduard Alexandru Bonci  15   16 , Andrei Pasca  15   16 , Isabel T Rubio  17 , Guldeniz Karadeniz Cakmak  18 , Michalis Kontos  19 , Thorsten Kühn  20
Affiliations

Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey

Maria Luisa Gasparri et al. Br J Surg. .

Abstract

Background: There is no consensus on axillary management after neoadjuvant therapy (NAT) in patients with clinically node-positive (cN+) breast cancer. To investigate current clinical practice, an international survey was conducted among breast surgeons and radiation oncologists. The aim of the first part of the survey was to provide a snapshot of international discrepancies regarding axillary surgery in this context.

Methods: The European Breast Cancer Research Association of Surgical Trialists (EUBREAST) developed a web-based survey containing 39 questions describing clinical scenarios in the setting of axillary management in patients with cN1 disease converting to ycN0 after NAT. The survey was then distributed to breast surgeons and radiation oncologists via 14 breast cancer societies between April and October 2021.

Results: Responses from 349 physicians in 45 countries were recorded. The most common post-NAT axillary surgery in patients with cN1 disease converting to ycN0 was targeted axillary dissection (54.2 per cent), followed by sentinel lymph node biopsy (SLNB) alone (20.9 per cent), level 1-2 axillary lymph node dissection (ALND) (18.4 per cent), level 1-3 ALND (4 per cent), and targeted lymph node biopsy (2.5 per cent). For SLNB alone, dual tracers were most commonly used (62.3 per cent). Management varied widely in patients with ambiguous axillary status before initiation of treatment or a residual metastatic burden in the axilla after NAT. In patients with ycN+ tumours, ALND was the preferred surgical approach for 66.8 per cent of respondents.

Conclusion: These results highlight the wide heterogeneity in surgical approaches to the axilla after NAT. To standardize the guidelines, further data from clinical research are urgently needed, which underlines the importance of the ongoing AXSANA (EUBREAST-3) study.

PubMed Disclaimer